Press Releases

Flagship Pioneering and its portfolio companies make news because of their transformative approaches to solving global challenges. If you have needs beyond these resources, please contact press@flagshippioneering.com.

company

year

domain

Syros Announces Appointment of Mark Alles to Its Board of Directors

Syros Pharmaceuticals 12.20.2019

GBT and Syros Partner to Discover, Develop and Commercialize Novel Therapies for Sickle Cell Disease and Beta Thalassemia

Syros Pharmaceuticals 12.18.2019

Flagship Pioneering Names Dr. Nancy Simonian, CEO of Syros, as Recipient of the 2019 Pioneering Leader Award

Syros Pharmaceuticals 12.02.2019

Syros Announces New Data from Phase 2 Trial of SY-1425 in Combination with Azacitidine Demonstrating High Response Rates, Rapid Onset of Action and Favorable Tolerability Profile in RARA-Positive Newly Diagnosed Unfit AML Patients

Syros Pharmaceuticals 10.24.2019

Syros Announces Update on Selective CDK7 Inhibitor Portfolio

Syros Pharmaceuticals 10.17.2019

New Publication in Cancer Research Highlights Discovery of SY-1365, a First-in-Class Selective CDK7 Inhibitor, and its Promise as a Potentially Transformative Targeted Approach for Difficult-to-Treat Cancers

Syros Pharmaceuticals 05.07.2019

Syros Announces Dose Escalation Data from Phase 1 Trial of SY-1365 Demonstrating Proof-of-Mechanism at Tolerable Doses in Patients with Advanced Solid Tumors

Syros Pharmaceuticals 11.15.2018

Syros Announces Appointment of Michael W. Bonney to Its Board of Directors

Syros Pharmaceuticals 06.14.2018

Syros Announces Appointment of Jeremy P. Springhorn as Chief Business Officer

Syros Pharmaceuticals 11.13.2017

Syros Receives FDA Orphan Drug Designation for SY-1425 for Treatment of AML

Syros Pharmaceuticals 08.21.2017

Loading